Phio Pharmaceuticals Corp. Uncategorized Contracts & Agreements
41 Contracts & Agreements
- Offer Letter, executed July 16, 2024, by and between the Company and Robert M. Infarinato (Filed With SEC on August 1, 2024)
- Form of Inducement Letter Agreement, dated July 12, 2024, by and between Phio Pharmaceuticals Corp. and the Holders (Filed With SEC on July 12, 2024)
- Description of Securities Registered Pursuant to Section 12(b) of the Securities Exchange Act of 1934 (Filed With SEC on April 1, 2024)
- Form of Inducement Letter Agreement, dated December 6, 2023, by and between Phio Pharmaceuticals Corp. and the Holders (Filed With SEC on December 8, 2023)
- Clinical Co-development Agreement, dated February 26, 2021, by and between Phio Pharmaceuticals Corp. and AgonOx, Inc (Filed With SEC on March 22, 2023)
- Description of Securities Registered Pursuant to Section 12(b) of the Securities Exchange Act of 1934 (Filed With SEC on March 26, 2020)
- Form of Placement Agent Warrants of Phio Pharmaceuticals Corp (Filed With SEC on November 20, 2019)
- 430 Park Avenue | New York, New York 10022 | 212 ###-###-#### | www.hcwco.com Member: FINRA/SIPC 1 (Filed With SEC on May 21, 2015)
- SEVENTH AMENDMENT AGREEMENT (Filed With SEC on May 14, 2012)
- SIXTH OMNIBUS AMENDMENT (Filed With SEC on May 14, 2012)
- FIFTH OMNIBUS AMENDMENT (Filed With SEC on May 14, 2012)
- FOURTH OMNIBUS AMENDMENT (Filed With SEC on May 14, 2012)
- THIRD OMNIBUS AMENDMENT (Filed With SEC on May 14, 2012)
- SECOND OMNIBUS AMENDMENT (Filed With SEC on May 14, 2012)
- OMNIBUS AMENDMENT (Filed With SEC on May 14, 2012)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on February 7, 2012)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on February 7, 2012)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on February 7, 2012)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on February 7, 2012)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on February 7, 2012)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on January 23, 2012)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on January 23, 2012)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on January 23, 2012)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on January 23, 2012)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on December 29, 2011)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on December 29, 2011)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on December 29, 2011)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on December 8, 2011)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on December 8, 2011)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on December 8, 2011)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on December 8, 2011)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on December 8, 2011)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on December 8, 2011)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on October 25, 2011)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on October 25, 2011)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on October 25, 2011)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on October 25, 2011)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on October 25, 2011)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on October 25, 2011)
- We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on October 25, 2011)
